OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
January 17 2023 - 6:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision
medicine company harnessing the power of molecular diagnostics and
bioinformatics to help combat infectious disease, today announced
that the Company has received confirmation from FIND, the global
alliance for diagnostics, that several key milestones under its
collaboration agreement with the global non-profit organization
have been successfully met as of the end of 2022. This achievement
has triggered an undisclosed milestone payment per the terms of the
agreement.
The completed milestone included several key
deliverables: successful demonstration of DNA isolation on the
Unyvero A30 cartridge from representative bacterial strains in
various types of blood culture bottles with subsequent PCR;
successful demonstration of several 3-plex assays from the intended
panel on the A30 cartridge with both pathogen detection as well as
AMR markers; and a detailed set of product requirements for the
target product profile, including a list of analytes to be detected
which has been defined. OpGen’s subsidiary Curetis furthermore
provided a report including results from its internal database
analysis looking at genetic diversity and resistance profiles in
pathogens observed in low and middle income countries (LMICs).
Also, a device specification for a prototype cockpit optimized for
use with the A30 platform has been defined and agreed upon.
Andreas Boos, Chief Technology Officer of
Curetis and program head for the Unyvero A30 platform development
commented, “We are excited about the progress that we have achieved
in a few short months since the start of our collaboration with
FIND and believe we are on track to achieve the remaining
milestones and complete the deliverables under this pilot project
as planned until the second quarter of this year.”
Johannes Bacher, Chief Operating Officer of
OpGen added that, “given the outstanding results and progress made
to date we look forward to a broader and expanded collaboration
with FIND once the remaining milestones have been demonstrated.
Such a next phase collaboration could include clinical studies as
well as projects toward certain regulatory filings in various
LMICs.”
Cecilia Ferreyra, Director, FIND AMR Programme
remarked that, “the R&D team at OpGen’s subsidiary Curetis has
worked to achieve important progress in a short period of time. We
are looking forward to seeing and evaluating this molecular point
of care test in the coming months as we continue working with the
team to evaluate the potential of Unyvero A30 to help identify
blood stream infections in patients admitted in LMICs
hospitals.”
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, U.S.A.) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH,
we are developing and commercializing molecular microbiology
solutions helping to guide clinicians with more rapid and
actionable information about life threatening infections to improve
patient outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s current
product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the
ARES Technology Platform including ARESdb, NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction including ARESiss, ARESid, and AREScloud, as well as the
Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
the Company’s collaboration with FIND. These statements and other
statements regarding OpGen’s future plans and goals constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Forward-looking statements may include, without
limitation, statements regarding the use of net proceeds therefrom.
Factors that could cause our results to differ materially from
those described include, but are not limited to, the success of our
commercialization efforts, our ability to successfully, timely and
cost-effectively develop, seek and obtain regulatory clearance for
and commercialize our product and services offerings, the rate of
adoption of our products and services by hospitals and other
healthcare providers, the fact that we may not effectively use
proceeds from this financing or other financings, the continued
realization of expected benefits of our business combination
transaction with Curetis GmbH, the continued impact of COVID-19 on
the Company’s operations, financial results, and commercialization
efforts as well as on capital markets and general economic
conditions, our ability to satisfy debt obligations under our loan
with the European Investment Bank, the effect of the military
action in Russia and Ukraine on our distributors, collaborators and
service providers, our liquidity and working capital requirements,
the effect on our business of existing and new regulatory
requirements, our ability to realize any anticipated benefits from
the reverse stock split, including maintaining its listing on the
Nasdaq Capital Market and attracting new investors, and other
economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen:Oliver SchachtPresident
and CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew
Bretzius FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:Alyssa
FactorEdison Groupafactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024